Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels. Suggestions for diagnostic procedures and monitoring

Digestive and Liver Disease

Volumn 40, Issue 7, 2008, Pages 585-598

  Morisco, F ^a   Pagliaro, L ^b   Caporaso, N ^a   Bianco, E ^c   Sagliocca, L ^d   Fargion, S ^e   Smedile, A ^f   Salvagnini, M ^g   Mele, A ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d G RUMMO HOSPITAL   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g Azienda Sanitaria Ulss 6 Vicenza   (Italy)

Author keywords

Aminotransferases elevation; Asymptomatic; Liver diseases; Non alcohol; Non virus

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CHELATE; COPPER; IMMUNOSUPPRESSIVE AGENT; METHYLDOPA; NITROFURANTOIN; PHENYLBUTAZONE; ZINC SULFATE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; CLINICAL TRIAL; CYTAPHERESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; GLUTEN FREE DIET; GRANULOMATOUS HEPATITIS; HEMOCHROMATOSIS; HUMAN; LABORATORY TEST; LIFESTYLE MODIFICATION; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WILSON DISEASE;

FATTY LIVER; HEPATITIS, ALCOHOLIC; HEPATITIS, VIRAL, HUMAN; HUMANS; ITALY; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; TRANSAMINASES;

EID: 44949241314     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.02.003     Document Type: Article

References (81)

1. Pendino G.M., Mariano A., Surace P., Caserta C.A., Fiorillo M.T., Amante A., et al. Prevalence and etiology of altered liver tests: a population-based Survey in a mediterranean town. Hepatology 41 (2005) 1151-1159
2. Bellentani S., Tiribelli C., Saccoccio G., Sodde M., Fratti N., De Martin C., et al. Prevalence of chronic liver disease in the general population of northern Italy: The Dionysos study. Hepatology 20 (1994) 1442-1449
3. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
4. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
5. Guidelines for the planning and management of NIH Consensus Development Conferences Online Bethesda (MD): National Institutes of Health, Office of the Director, Office of Medical Applications of Research; 1993 May. Updated October 2001.
6. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-9
7. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
8. Kim H.C., Nam C.M., Jee S.H., Han K.H., Oh D.K., and Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J 328 (2004) 983
9. Prati D., Shiffman M.L., Diago M., Gane E., Rajender Reddy K., Pockros P., et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 44 (2006) 679-685
10. Kaplan M.M. Alanine Aminotransferase levels: what's normal?. Ann Intern Med 137 (2002) 49-51
11. Kunde S.S., Lazenby A.J., Clements R.H., and Abrams G.A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 42 (2005) 650-656
12. Puoti C., Guido M., Mangia A., Persico M., and Prati D. The Committee on HCV carriers with normal aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liv Dis 35 (2003) 362-369
13. Daniel S., Ben-Menachem T., Vasudevan G., Ma C.K., and Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 (1999) 3010-3014
14. Sherwood P., Lyburn I., Brown S., and Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact?. Br Med J 322 (2001) 276-278
15. Skelly M.M., James P.D., and Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 (2001) 195-199
16. Approach to the patient with abnormal liver function tests. UpToDate 14, Feb. 2006. www.uptodate.com.
17. Pratt D., and Kaplan M.M. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
18. American Gastroenterological Association Medical Position Statement: Evaluation of liver chemistry tests. Gastroenterology 2005;123:1364-6.
19. Green R.M., and Flamm S. AGA Technical review on the evaluation of liver chemistry tests. Gastroenterology 123 (2005) 1367-1384
20. US Preventive Services Task Force. Screening and behavioural counselling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 140 (2004) 554-556
21. Patt C.H., Yoo H.Y., Dibadj K., Flynn J., and Thuluvath P.J. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci 48 (2003) 797-801
22. Litin S.C., O'Brien J.F., Pruett S., Forsman R.W., Burritt M.F., Bartholomew L.G., et al. Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. Mayo Clin Proc 62 (1987) 681-687
23. Briani C., Zaninotto M., Forni M., and Burra P. Macroenzymes: too often overlooked. J Hepatol 38 (2003) 119
24. Berasain C., Betés M., Panizo A., Ruiz J., Herrero J.I., Civeira M.P., et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 47 (2000) 429-435
25. Mathiesen U.L., Franzén L.E., Frydén A., Foberg U., and Bodemar G. The clinical significance of slightly to moderately increased liver transaminases values in asymptomatic and symptomatic patients. Scand J Gastroenterol 34 (1999) 85-91
26. Hultcrantz R., Glaumann H., Lindberg G., and Nilsson L.H. Liver investigation in 149 asymptomtic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 21 (1986) 109-113
27. Katkov W.N., Friedman L.S., Cody H., Evans A., Kuo G., Choo Q.L., et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med 115 (1991) 882-884
28. Kundrotas L.W., and Clement D.J. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 38 (1993) 2145-2150
29. Omagari K., Kadokawa Y., Masuda J., Egawa I., Sawa T., Hazama H., et al. Non alcoholic fatty liver in Japan. Fatty liver in non-alcoholic nonoverweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 17 (2002) 1098-1105
30. Yu A.S., and Keeffe E.B. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol 98 (2003) 955-956
31. Volta U., De Franceschi L., Lari F., Molinaro N., Zoli M., and Bianchi F.B. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 352 (1998) 26-29
32. Bardella M.T., Vecchi M., Conte D., Del Ninno E., Fraquelli M., Pacchetti S., et al. Chronic unexplained hypertransaminasaemia may be caused by occult celiac disease. Hepatology 29 (1999) 654-657
33. Volta U., Granito A., De Franceschi L., Petrolini N., and Bianchi F.B. Anti tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Digest Liver Dis 33 (2001) 420-425
34. Bhavnani M., Lloyd D., Bhattacharyya A., Marples J., Elton P., and Worwood M. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase. Gut 46 (2000) 707-710
35. Morisco F., Di Lonardo A., Stroffolini T., Leone D., and Caporaso N. High prevalence of non-virus/non-alcohol-related alanine-aminotransferase increase in blood donors. Haematologica 86 (2001) 1116
36. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002) 451-455
37. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
38. Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 61 (2005) 135-143
39. Maddrey W.C. Clinicopathological patterns of drug-induced liver disease. In: Kaplowitz M., and DeLeve L.D. (Eds). Drug-induced Liver Disease (2003), Marcel Dekker, New York 227-242
40. Tolman K.G. Occupational and environmental hepatotoxicity. In: Kaplowitz N., and DeLeve L.D. (Eds). Drug-induced liver disease (1993), Marcel Dekker, Inc., New York 725-738
41. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005;128:S1-S9.
42. Adams P., Brissot P., and Powell L.W. EASL International Conference on Hemochromatosis. J Hepatol 33 (2000) 485-504
43. Tavill A.S., and American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 33 (2001) 1321-1328
44. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 (2004) 2383-2397
45. Roberts E.A., and Schilsky M.L. AASLD Practice Guidelines. A Practice Guidlines on Wilson Disease. Hepatology 37 (2003) 1475-1492
46. Brewer G.J., and Askari F.K. Wilson's disease: clinical management and therapy. J Hepatol 42 (2005) S13-S24
47. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
48. Czaja A.J., Bianchi F.B., Carpenter H.A., Krawitt E.L., Lohse A.W., Manns M.P., et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 41 (2005) 207-215
49. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27 (1997) 103-107
50. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43 (2005) 1060-1066
51. Fagan T.J. Nomogram for Bayes's theorem. N Engl J Med 293 (1975) 257
52. Neuschwander-Tetri B.A., and Caldwell S.H. Non-alcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37 (2003) 1202-1219
53. Palmentieri B., de Sio I., La Mura V., Masarone M., Vecchione R., Bruno S., et al. The role of bright liver echopattern on ultrasound B mode examination in the diagnosis of liver steatosis. Dig Liv Dis 38 (2006) 485-489
54. Mathiesen U.L., Franzén L.E., Aselius H., Resjö M., Jacobsson L., Foberg U., et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but no fibrosis in asymptomatic patients with mild-moderate abnormalities of liver transaminases. Dig Liv Dis 34 (2002) 516-522
55. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
56. Farrell R.J., and Kelly C.P. Celiac sprue. N Engl J Med 346 (2002) 180-188
57. Vajro P., Fontanella A., Mayer M., De Vincenzo A., Terracciano L.M., D'Armiento M., et al. Elevated serum aminotrasferase activity as a presentation of gluten-sensitive enteropathy. J Pediatr 122 (1993) 416
58. Rostami K., Kerckhaert J., Tiemessen R., von Blomberg B.M., Meijer J.W., and Mulder C.J. Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: disappointing in clinical practice. Am J Gastroenterol 94 (1999) 888-894
59. Dieterich W., Laag E., Schöpper H., Volta U., Ferguson A., Gillett H., et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 115 (1998) 1317-1321
60. Sulkanen S., Halttunen T., Laurila K., Kolho K.L., Korponay-Szabó I.R., Sarnesto A., et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 115 (1998) 1322-1328
61. Louka A.S., and Sollid L.M. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 61 (2003) 105-117
62. Bulaj Z.J., Ajioka R.S., Phillips J.D., LaSalle B.A., Jorde L.B., Griffen L.M., et al. Disease related conditions in relatives of patients with hemochromatosis. N Engl J Med 343 (2000) 1529-1535
63. Powell L.W., George D.K., McDonnell S.M., and Kowdley K.V. Diagnosis of hemochromatosis. Ann Intern Med 129 (1998) 925-931
64. Koziol J.A., Felitti V.J., and Beutler E. The effect of HFE Genotypes on measurements of iron overload. Ann Intern Med 137 (2002) 700-701. ripreso in UpToDate 13-3-2005. http://www.uptodate.com
65. Kaplan MM. Diagnosis of Wilson's disease. UpToDate 13-3-2005. http://www.uptodate.com.
66. Brewer G.J., and Yuzbasiyan-Gurkan V. Wilson's Disease. Medicine 71 (1992) 139-164
67. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 354 (2006) 54-66
68. Hennes E.M., Zeniya M., Czaja A.J., Pares A., Dalekos G., Krawitt E., et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology 42 Suppl.1 (2005) 295 abs 248
69. Sherlock S. The presentation and diagnosis of 100 patients with primari biliary cirrhosis. In: Schaffner F., Sherlock S., and Leevy C.M. (Eds). The Liver and its diseases (1974), Intercontinental Medical Book Corporation, New York 227-235
70. Christensen E., Crowe J., Doniach D., Popper H., Ranek L., Rodés J., et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78 (1980) 236-246
71. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 335 (1996) 1570-1580
72. Van de Water J., Cooper A., Surh C.D., Coppel R., Danner D., Ansari A., et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 320 (1989) 1377-1380
73. Invernizzi P., Crosignani A., Battezzati P.M., Covini G., De Valle G., Larghi A., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody positive and negative primary biliary cirrhosis. Hepatology 25 (1997) 1090-1095
74. MacFaul G.R., and Chapman R.W. Sclerosing cholangitis. Curr Opin Gastroenterol 20 (2004) 275-280
75. Loftus Jr. E.V., Harewood G.C., Loftus C.G., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54 (2005) 91-99
76. Terjung B., and Worman H.J. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15 (2001) 629-642
77. Wiencke K., Karlsen T.H., Boberg K.M., Thorsby E., Schrumpf E., Lie B.A., et al. Primary Sclerosing Cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens 69 (2007) 161-169
78. Muratori P., Muratori L., Gershwin M.E., Czaja A.J., Pappas G., MacCariello S., et al. "True" antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol 135 (2004) 154-158
79. Valenti L., Dongiovanni P., Piperno A., Fracanzani A.L., Maggioni M., Rametta R., et al. Alfa-1 antitrypsin mutations in patients with NAFLD: a high prevalence with altered iron metabolism but not with liver damage. Hepatology 44 (2006) 857-864
80. De Serres F.J., Blanco I., and Fernàndez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin in southern Europe: France, Italy, Portugal and Spain. Clin Genet 63 (2003) 490-509
81. Ferrarotti I., Baccheschi J., Zorzetto M., Tinelli C., Corda L., Balbi B., et al. Prevalence and phenotype of subjects carrying rare phenotype of subjects carrying rare variants in the Italian registry for alpha-1 antitrypsin deficiency. J Med Genet 42 (2005) 282-287